Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a leading global gastrointestinal (GI) healthcare company committed to advancing the treatment of GI diseases and redefining the standard of care for patients. They are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets.

Ironwood is a patient-focused organization that places high value on sustainability in everything they do. Their company culture is designed to be inclusive, ethical, and responsible, striving to make a positive impact on the health and lives of GI patients, their families, and communities. They are committed to clinical trial diversity, responsible research practices, and giving back through philanthropy.

Ironwood Pharmaceuticals offers a hybrid work environment, allowing most employees the flexibility to work remotely or in the office. While their headquarters employees typically come together 3-5 days each month to foster their collaborative culture, the company prioritizes personal autonomy and accountability, providing employees with resources and investing in hybrid technologies to optimize their productivity and respect their personal needs and choices.

Ironwood Pharmaceuticals offers a competitive benefits package designed to support the well-being of its employees and their families. Benefits include equity in the form of restricted stock units, biannual opportunities to buy company shares at a discount, health and wellness programs, retirement savings plans, commuting assistance, generous time off, educational opportunities, and company-sponsored community outreach programs.

Ironwood Pharmaceuticals is a leading global gastrointestinal (GI) healthcare company committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. They strive to reduce the burden of GI diseases and address significant unmet needs by pioneering innovative medicines and prioritizing patient-centric research and commercialization efforts.

Ironwood Pharmaceuticals cultivates a collaborative, supportive, and inclusive culture that values diversity, innovation, and a strong work-life balance. The company encourages its employees to think differently, challenge the status quo, and take ownership of their work, while providing a flexible work environment that includes hybrid options and a focus on employee well-being.

Ironwood Pharmaceuticals is committed to fostering a culture of belonging where every employee feels valued and empowered. They prioritize diversity, equity, and inclusion in all aspects of their operations, with a focus on creating an equitable workplace and fostering a sense of belonging for all. They have implemented several initiatives to support their commitment to DEI, including employee resource groups like W@IRWD for women, ISHINE internship program for students from historically Black colleges and universities, and IMPACT for community engagement, all aimed at creating a diverse and inclusive environment.